Nektar Therapeutics (NKTR) to Release Quarterly Earnings on Thursday

Posted by Hanz Christensen on Nov 1st, 2024

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) is scheduled to release its earnings data after the market closes on Thursday, November 7th. Analysts expect Nektar Therapeutics to post earnings of ($0.23) per share for the quarter.

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.25) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.04). Nektar Therapeutics had a negative net margin of 190.09% and a negative return on equity of 133.64%. The business had revenue of $23.49 million for the quarter, compared to analysts’ expectations of $17.24 million. During the same quarter last year, the business posted ($0.27) earnings per share. On average, analysts expect Nektar Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Nektar Therapeutics Price Performance

Shares of NASDAQ NKTR opened at $1.22 on Friday. The firm’s 50-day moving average is $1.28 and its two-hundred day moving average is $1.34. Nektar Therapeutics has a 12-month low of $0.41 and a 12-month high of $1.93. The company has a market capitalization of $223.66 million, a PE ratio of -1.35 and a beta of 0.60.

Wall Street Analyst Weigh In

Separately, BTIG Research reissued a “buy” rating and issued a $4.00 price objective on shares of Nektar Therapeutics in a research report on Monday, September 30th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $2.33.

Check Out Our Latest Research Report on NKTR

Nektar Therapeutics Company Profile

(Get Free Report)

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.